355 related articles for article (PubMed ID: 23643400)
21. Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload.
Daar S; Pathare AV
Ann Hematol; 2006 May; 85(5):315-9. PubMed ID: 16450126
[TBL] [Abstract][Full Text] [Related]
22. Absence of cardiac siderosis by MRI T2* despite transfusion burden, hepatic and serum iron overload in Lebanese patients with sickle cell disease.
Inati A; Musallam KM; Wood JC; Sheikh-Taha M; Daou L; Taher AT
Eur J Haematol; 2009 Dec; 83(6):565-71. PubMed ID: 19737308
[TBL] [Abstract][Full Text] [Related]
23. Iron chelation therapy in the management of transfusion-related cardiac iron overload.
Fernandes JL
Transfusion; 2012 Oct; 52(10):2256-68. PubMed ID: 22404719
[TBL] [Abstract][Full Text] [Related]
24. Magnetic resonance imaging in the evaluation of iron overload in patients with beta thalassaemia and sickle cell disease.
Voskaridou E; Douskou M; Terpos E; Papassotiriou I; Stamoulakatou A; Ourailidis A; Loutradi A; Loukopoulos D
Br J Haematol; 2004 Sep; 126(5):736-42. PubMed ID: 15327528
[TBL] [Abstract][Full Text] [Related]
25. Impact of heart magnetic resonance imaging on chelation choices, compliance with treatment and risk of heart disease in patients with thalassaemia major.
Origa R; Danjou F; Cossa S; Matta G; Bina P; Dessì C; Defraia E; Foschini ML; Leoni G; Morittu M; Galanello R
Br J Haematol; 2013 Nov; 163(3):400-3. PubMed ID: 24033185
[TBL] [Abstract][Full Text] [Related]
26. Pituitary iron and volume predict hypogonadism in transfusional iron overload.
Noetzli LJ; Panigrahy A; Mittelman SD; Hyderi A; Dongelyan A; Coates TD; Wood JC
Am J Hematol; 2012 Feb; 87(2):167-71. PubMed ID: 22213195
[TBL] [Abstract][Full Text] [Related]
27. Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload.
Nolte F; Höchsmann B; Giagounidis A; Lübbert M; Platzbecker U; Haase D; Lück A; Gattermann N; Taupitz M; Baier M; Leismann O; Junkes A; Schumann C; Hofmann WK; Schrezenmeier H
Ann Hematol; 2013 Jan; 92(2):191-8. PubMed ID: 23073603
[TBL] [Abstract][Full Text] [Related]
28. Combined iron chelation therapy.
Galanello R; Agus A; Campus S; Danjou F; Giardina PJ; Grady RW
Ann N Y Acad Sci; 2010 Aug; 1202():79-86. PubMed ID: 20712777
[TBL] [Abstract][Full Text] [Related]
29. Measurement and mapping of liver iron concentrations using magnetic resonance imaging.
St Pierre TG; Clark PR; Chua-Anusorn W
Ann N Y Acad Sci; 2005; 1054():379-85. PubMed ID: 16339686
[TBL] [Abstract][Full Text] [Related]
30. Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: a literature review.
Delea TE; Edelsberg J; Sofrygin O; Thomas SK; Baladi JF; Phatak PD; Coates TD
Transfusion; 2007 Oct; 47(10):1919-29. PubMed ID: 17880620
[TBL] [Abstract][Full Text] [Related]
31. Concepts and goals in the management of transfusional iron overload.
Porter JB
Am J Hematol; 2007 Dec; 82(12 Suppl):1136-9. PubMed ID: 17968973
[TBL] [Abstract][Full Text] [Related]
32. A new era in iron chelation therapy: the design of optimal, individually adjusted iron chelation therapies for the complete removal of iron overload in thalassemia and other chronically transfused patients.
Kontoghiorghes GJ
Hemoglobin; 2009; 33(5):332-8. PubMed ID: 19814679
[TBL] [Abstract][Full Text] [Related]
33. Reduction of body iron stores to normal range levels in thalassaemia by using a deferiprone/deferoxamine combination and their maintenance thereafter by deferiprone monotherapy.
Kolnagou A; Kleanthous M; Kontoghiorghes GJ
Eur J Haematol; 2010 Nov; 85(5):430-8. PubMed ID: 20662901
[TBL] [Abstract][Full Text] [Related]
34. Myocardial iron overload assessed by magnetic resonance imaging (MRI)T2* in multi-transfused patients with thalassemia and acquired anemias.
Fragasso A; Ciancio A; Mannarella C; Gaudiano C; Scarciolla O; Ottonello C; Francone M; Nardella M; Peluso A; Melpignano A; Veglio MR; Quarta G; Turchetti C
Eur J Intern Med; 2011 Feb; 22(1):62-5. PubMed ID: 21238896
[TBL] [Abstract][Full Text] [Related]
35. Deferasirox administration for the treatment of non-transfusional iron overload in patients with thalassaemia intermedia.
Ladis V; Berdousi H; Gotsis E; Kattamis A
Br J Haematol; 2010 Dec; 151(5):504-8. PubMed ID: 20950401
[TBL] [Abstract][Full Text] [Related]
36. A randomized controlled study evaluating the safety and efficacy of deferiprone treatment in thalassemia major patients from Hong Kong.
Ha SY; Chik KW; Ling SC; Lee AC; Luk CW; Lam CW; Ng IO; Chan GC
Hemoglobin; 2006; 30(2):263-74. PubMed ID: 16798652
[TBL] [Abstract][Full Text] [Related]
37. Consequences and management of iron overload in sickle cell disease.
Porter J; Garbowski M
Hematology Am Soc Hematol Educ Program; 2013; 2013():447-56. PubMed ID: 24319218
[TBL] [Abstract][Full Text] [Related]
38. A practical chelation protocol based on stratification of thalassemic patients by serum ferritin and magnetic resonance imaging cardiac T2*.
Ha SY; Mok AS; Chu WC; Raskalkar DD; Cheuk DK; Chiang AK; Ho MH; Chan GC
Hemoglobin; 2009; 33(5):323-31. PubMed ID: 19814678
[TBL] [Abstract][Full Text] [Related]
39. Effects of chelation therapy on cardiac function improvement in thalassemia patients: literature review and the Taiwanese experience.
Peng CT; Tsai CH; Wu KH
Hemoglobin; 2008; 32(1-2):49-62. PubMed ID: 18274983
[TBL] [Abstract][Full Text] [Related]
40. Effect of deferiprone on liver iron overload and fibrosis in hepatitis-C-virus-infected thalassemia.
Chen AC; Peng CT; Wu SF; Wu KH; Chiang IP; Tsai CH
Hemoglobin; 2006; 30(2):209-14. PubMed ID: 16798645
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
